Cite
HARVARD Citation
Choueiri, T. et al. (2023). Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet oncology. 24 (3), pp. 228-238. [Online].